866-997-4948(US-Canada Toll Free)

PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services

Published By :

GlobalData

Published Date : Jan 2017

Category :

Pharmaceutical

No. of Pages : 23 Pages

PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services

Summary

Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs. Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in getting clinical trial materials needed for studies.

According to this latest report, "PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services", the driver of this early development activity has been the huge level of external funding flowing into emerging bio/pharma companies from venture capitalists and public markets. However, external funding for bio/pharma has always been a boom or bust proposition, and the likelihood that funding will be cut drastically always lurks on the horizon. This makes it difficult for CDMOs and CROs to pull the trigger on investments in new capacity.

Scope

- Follow the Money: The Outlook for Outsourced Spending on Early Development Services exams the link between external funding sources and early drug development, and addresses the outlook for continued funding over the next two years.

Reasons to buy

This report provides important insight that you wont find in any other source. This report is required reading for -
- CDMOs and CROs: market trends, capital investment decision-making, strategic planning, performance benchmarking
- Bio/pharma: supplier performance benchmarking, market trends, competitive intelligence
- Private equity: investment targeting, portfolio company performance benchmarking
1 Table of Contents
Executive Summary 1
Context and Objectives 2
Clinical Trial Activity of Emerging Bio/Pharma Companies 4
Clinical Development Costs and Spending by Emerging Bio/Pharma Companies 7
External Financing for Emerging Bio/Pharma Companies 9
Outlook and What it Means 15
Appendix A 18
Appendix B 19

1.1 List of Tables
Table 1 2016 Performance of Drug Development Service Providers
Table 2 Profile of Emerging Bio/Pharma IPOs 2014-2015

1.2 List of Figures
Figure 1 Breakdown of Phase I and Phase II Trials by Primary Sponsor, H1 2012-H1 2016
Figure 2 Operating Expenditure of US Emerging Biopharma Companies Pre- and Post-IPO
Figure 3 Operating Expenditure of US Emerging Biopharma Companies Pre- and Post-SPO
Figure 4 Estimated Cost of Getting Candidates Through Clinical Trial Phases
Figure 5 Ownership of Emerging Bio/Pharma Companies Sponsoring Clinical Trials H1 2016
Figure 6 Equity Funding to Emerging Bio/Pharma 2010-2016
Figure 7 Venture Capital Investment in Bio/Pharma Companies
Figure 8 VC Funding to Emerging Bio/Pharma 2010-2015
Figure 9 NASDAQ Biotech Index January 13-December 2016
Figure 10 R&D Spend and Cash Runway for US Emerging Bio/Pharma Companies
Figure 11 Revenue as a Funding Source for US Emerging BioPharma
Figure 12 Proportion of Companies with > 2 Years Cash or Increasing Cash Reserves

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *